IMS to Combine Largest U.S. Health Plan Claims Database with IMS LifeLink, Enabling Innovative Patient Treatment Insights

<0> IMS HealthTracy Everly, + 1-610-244-2600 </0>

IMS Health has signed a collaboration agreement with Health Intelligence Company LLC (HIC), which operates as Blue Health Intelligence, to leverage HIC’s secure healthcare claims database in IMS solutions, enabling biopharmaceutical organizations to advance the delivery of high-quality, cost-efficient care. The HIC database represents the industry’s most comprehensive and diverse commercial health plan claims database in the U.S.

Spanning all U.S. geographies, settings of care and therapy areas, the HIC database complies with Health Insurance Portability and Accountability Act (HIPAA) patient privacy safeguards. It will become part of the portfolio of patient-centered information, analytics and services, which presents a robust view of treatment decisions for more than 210 million de-identified patients in the U.S. The new capabilities will be offered as .

By establishing the industry’s most robust Real-World Evidence (RWE) platform, IMS is uniquely positioned to support the full range of activities required by healthcare stakeholders to examine the cost and effectiveness of medicines and health technologies. The agreement expands IMS’s extensive information assets and ability to link industry-leading healthcare information, including prescription drug, electronic medical record, hospital services and demographic data. The HIC database includes more than 110 million de-identified, commercially insured health plan members covered since 2005.

“By bringing together the collective data and intelligence of IMS and HIC, we are enabling decision makers to access, manage and gain insights about the total patient experience in near real time,” says Andrew Kress, senior vice president, IMS Healthcare Value Solutions. “We recognize the increasing interconnectedness of healthcare stakeholders, and the power of applying technology to provide integrated patient-level insights to inform the healthcare quality and value dialogue.”

Available this month, will be a foundational component of IMS’s expanded RWE platform supporting a broad range of applications, from epidemiological studies and comparative effectiveness and safety research, to commercial analytics. New treatment and outcomes insights will be enabled through a number of unique platform features, including:

“We are very pleased to enter this agreement with IMS,” said Swati Abbott, CEO of HIC. “It will accelerate our mission to leverage healthcare informatics to identify and drive gains in efficiencies and effective solutions across the healthcare system.”

Health Intelligence Company is the nation’s premier health intelligence resource, delivering data-driven insights about healthcare trends and best practices, resulting in healthier lives and more affordable access to safe and effective care. HIC accesses healthcare claims data from more than 110 million individuals nationwide, collected over seven years, in a safe, HIPAA compliant and secure database. The resulting conformed, reliable data set has the broadest, deepest pool of integrated medical and pharmacy claims, reflecting medical utilization in every ZIP code. Blue Health Intelligence (BHI) is a trade name of Health Intelligence Company LLC. BHI is an Independent Licensee of the Blue Cross and Blue Shield Association. For more information, visit .

IMS Health is a leading provider of information, services and technology for the healthcare industry around the world. The company draws on its global technology infrastructure and unique combination of in-depth, sophisticated analytics, on-shore and off-shore commercial services, and software platforms to help clients better understand the performance and dynamics of healthcare systems. With a presence in 100+ countries and more than 55 years of industry experience, IMS serves leading decision makers in healthcare, including pharmaceutical manufacturers and distributors, providers, payers, government agencies, policymakers, researchers and the financial community. Additional information is available at .